Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer

By sjmartinez • October 26, 2023

Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi: 10.1016/j.jtcvs.2022.10.007. Epub 2022 Oct 8. PMID: 36369159; PMCID: PMC10288861.

Tags: Hematology/Oncology, immunotherapy, Lung cancer, neoadjuvant therapy, Publications

Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models

Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg[...]